Clinical cases
THERAPEUTIC SUCCESS WITH BRENTUXIMAB IN ADVANCED MF WITH MAJOR SKIN INVOLVEMENT. CLINICAL CASE

Summary

Mycosis fungoides is the commonest type of primary, a form of non-Hodgkin characterised clinically by lesional progression from patches to plaques to tumours.It can begin as chronic itching, even before the appearance of clinical signs of the disease. Specific serological investigations, lymph node biopsy and imaging may be required if there is concern the skin lesions are secondary to a systemic lymphoma or in advanced disease (ie, extracutaneous spread).We are presenting the case of a 54- year-old female patient, smoker, known with mycosis fungoides since 2007 and diagnosed in our Clinic in 2014, currently being treated with acitretin 40 mg per day, who presented for control due to the appearance of a left submandibular tumefaction with pre and retroauricular extension, imprecisely delimited, with a firm consistency and slightly painful to the touch, with modified overlying skin (ulcerated tumour plaque, with thick serohematic crust on the surface).Apuncture-biopsy was performed on the left submandibular lymphadenopathy, the appearance being of aggressive non-Hodgkin’s lymphoma (ki67=70%), CD30+, reason why it was decided to initiate the therapy with Brentuximab vedotin, a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells.